Synthetic Immunology: Hacking Immune Cells to Expand Their Therapeutic Capabilities

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989 · see citing works

Microenvironmental regulation of tumor progression and metastasis

Quail, D. F., & Joyce, J. A. (2013) · Nature Medicine · doi:10.1038/nm.3394 · Cited by 7,994 · see citing works

Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802 · see citing works

Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment

Hanahan, D., & Coussens, L. M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.022 · Cited by 4,632 · see citing works

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286 · see citing works

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509 · see citing works

Molecular mechanisms of T cell co-stimulation and co-inhibition

Chen, L., & Flies, D. B. (2013) · Nature Reviews Immunology · doi:10.1038/nri3405 · Cited by 3,114 · see citing works

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898 · see citing works

Notch signalling: a simple pathway becomes complex

Bray, S. J. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2009 · Cited by 2,620 · see citing works

Cancer regression in patients after transfer of genetically engineered lymphocytes

Morgan, R. A., Dudley, M. E., Wunderlich, J. R., Hughes, M. S., Yang, J. C., Sherry, R. M., Royal, R. E., Topalian, S. L., Kammula, U. S., Restifo, N. P., et al. (2006) · Science · doi:10.1126/science.1129003 · Cited by 2,603 · see citing works

T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia

Kalos, M. D., Levine, B. L., Porter, D. L., Katz, S. I., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,389 · see citing works

Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential

Sharma, P., & Allison, J. P. (2015) · Cell · doi:10.1016/j.cell.2015.03.030 · Cited by 2,345 · see citing works

Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy

Rosenberg, S. A., Yang, J. C., Sherry, R. M., Kammula, U. S., Hughes, M. S., Phan, G. Q., Citrin, D. E., Restifo, N. P., Robbins, P. F., Wunderlich, J. R., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0116 · Cited by 2,145 · see citing works

CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia

Brentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005930 · Cited by 2,063 · see citing works

Cancer immunotherapy via dendritic cells

Palucka, K., & Banchereau, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3258 · Cited by 2,060 · see citing works

The microbiome and innate immunity

Thaiss, C. A., Zmora, N., Levy, M., & Elinav, E. (2016) · Nature · doi:10.1038/nature18847 · Cited by 2,012 · see citing works

Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia

Porter, D. L., Hwang, W.-T., Frey, N. V., Lacey, S. F., Shaw, P. A., Loren, A. W., Bagg, A., Marcucci, K. T., Shen, A., Gonzalez, V., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac5415 · Cited by 1,729 · see citing works

Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors.

Eshhar, Z., Waks, T., Gross, G., & Schindler, D. G. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.2.720 · Cited by 1,668 · see citing works

Up on the tightrope: natural killer cell activation and inhibition

Lanier, L. L. (2008) · Nature Immunology · doi:10.1038/ni1581 · Cited by 1,656 · see citing works

Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1

Robbins, P. F., Morgan, R. A., Feldman, S. A., Yang, J. C.-H., Sherry, R. M., Dudley, M. E., Wunderlich, J. R., Nahvi, A. V., Helman, L. J., Mackall, C. L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.2537 · Cited by 1,635 · see citing works

Notch-1 signalling requires ligand-induced proteolytic release of intracellular domain

Schroeter, E. H., Kisslinger, J. A., & Kopan, R. (1998) · Nature · doi:10.1038/30756 · Cited by 1,624 · see citing works

Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity.

Gross, G., Waks, T., & Eshhar, Z. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.24.10024 · Cited by 1,597 · see citing works

Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor

Kochenderfer, J. N., Dudley, M. E., Kassim, S. H., Somerville, R. P. T., Carpenter, R. O., Stetler-Stevenson, M., Yang, J. C., Phan, G. Q., Hughes, M. S., Sherry, R. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2025 · Cited by 1,595 · see citing works

Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy

Di Stasi, A., Tey, S.-K., Dotti, G., Fujita, Y., Kennedy-Nasser, A., Martinez, C., Straathof, K., Liu, E., Durett, A. G., Grilley, B., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1106152 · Cited by 1,512 · see citing works

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor–transduced T cells

Kochenderfer, J. N., Dudley, M. E., Feldman, S. A., Wilson, W. H., Spaner, D., Marić, I., Stetler‐Stevenson, M., Phan, G. Q., Hughes, M. S., Sherry, R. M., et al. (2011) · Blood · doi:10.1182/blood-2011-10-384388 · Cited by 1,441 · see citing works

The basic principles of chimeric antigen receptor (CAR) design

Sadelain, M., Brentjens, R., & Rivière, I. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0548 · Cited by 1,423 · see citing works

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen

Johnson, L. A., Morgan, R. A., Dudley, M. E., Cassard, L., Yang, J. C.-H., Hughes, M. S., Kammula, U. S., Royal, R. E., Sherry, R. M., Wunderlich, J. R., et al. (2009) · Blood · doi:10.1182/blood-2009-03-211714 · Cited by 1,421 · see citing works

Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19

Kochenderfer, J. N., Wilson, W. H., Janik, J. E., Dudley, M. E., Stetler-Stevenson, M., Feldman, S. A., Maric, I., Raffeld, M., Nathan, D.-A. N., Lanier, B. J., et al. (2010) · Blood · doi:10.1182/blood-2010-04-281931 · Cited by 1,337 · see citing works

Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens

Dudley, M. E., Yang, J. C., Sherry, R. M., Hughes, M. S., Royal, R. E., Kammula, U. S., Robbins, P. F., Huang, J., Citrin, D. E., Leitman, S. F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.5449 · Cited by 1,334 · see citing works

Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias

Brentjens, R. J., Rivière, I., Park, J. H., Davila, M. L., Wang, X., Stefanski, J., Taylor, C., Yeh, R., Bartido, S. M., Bórquez-Ojeda, O., et al. (2011) · Blood · doi:10.1182/blood-2011-04-348540 · Cited by 1,287 · see citing works

Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells

Kawalekar, O. U., O’Connor, R. S., Fraietta, J. A., Guo, L., McGettigan, S. E., Posey, A. D., Patel, P. R., Guedan, S., Scholler, J., Keith, B., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.01.021 · Cited by 1,234 · see citing works

Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo

Milone, M. C., Fish, J. D., Carpenito, C., Carroll, R. G., Binder, G. K., Teachey, D., Samanta, M., Lakhal, M., Gloss, B., Danet-Desnoyers, G., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.83 · Cited by 1,197 · see citing works

Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma

Linette, G. P., Stadtmauer, E. A., Maus, M. V., Rapoport, A. P., Levine, B. L., Emery, L., Litzky, L. A., Bagg, A., Carreno, B. M., Cimino, P. J., et al. (2013) · Blood · doi:10.1182/blood-2013-03-490565 · Cited by 1,183 · see citing works

HSV-TK Gene Transfer into Donor Lymphocytes for Control of Allogeneic Graft-Versus-Leukemia

Bonini, C., Ferrari, G., Verzeletti, S., Servida, P., Zappone, E., Ruggieri, L., Ponzoni, M., Rossini, S., Mavilio, F., Traversari, C., et al. (1997) · Science · doi:10.1126/science.276.5319.1719 · Cited by 1,158 · see citing works

Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy

Morgan, R. A., Chinnasamy, N., Abate‐Daga, D., Gros, A., Robbins, P. F., Zheng, Z., Dudley, M. E., Feldman, S. A., Yang, J. C., Sherry, R. M., et al. (2013) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3182829903 · Cited by 1,155 · see citing works

Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor

Maher, J. F., Brentjens, R. J., Gunset, G., Rivière, I., & Sadelain, M. (2002) · Nature Biotechnology · doi:10.1038/nbt0102-70 · Cited by 1,031 · see citing works

T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis

Parkhurst, M. R., Yang, J. C.-H., Langan, R. C., Dudley, M. E., Nathan, D.-A. N., Feldman, S. A., Davis, J. L., Morgan, R. A., Merino, M. J., Sherry, R. M., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.272 · Cited by 1,025 · see citing works

Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits

Roybal, K. T., Rupp, L. J., Morsut, L., Walker, W. J., McNally, K. A., Park, J. S., & Lim, W. A. (2016) · Cell · doi:10.1016/j.cell.2016.01.011 · Cited by 1,010 · see citing works

Engineering Customized Cell Sensing and Response Behaviors Using Synthetic Notch Receptors

Morsut, L., Roybal, K. T., Xiong, X., Gordley, R. M., Coyle, S. M., Thomson, M., & Lim, W. A. (2016) · Cell · doi:10.1016/j.cell.2016.01.012 · Cited by 1,002 · see citing works

Coinhibitory Pathways in Immunotherapy for Cancer

Baumeister, S. H. C., Freeman, G. J., Dranoff, G., & Sharpe, A. H. (2016) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032414-112049 · Cited by 912 · see citing works

Dendritic Cells Prime Natural Killer Cells by trans-Presenting Interleukin 15

Lucas, M., Schachterle, W., Oberle, K., Aichele, P., & Diefenbach, A. (2007) · Immunity · doi:10.1016/j.immuni.2007.03.006 · Cited by 888 · see citing works

Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells

Kloss, C. C., Condomines, M., Cartellieri, M., Bachmann, M. P., & Sadelain, M. (2012) · Nature Biotechnology · doi:10.1038/nbt.2459 · Cited by 860 · see citing works

NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma

Rapoport, A. P., Stadtmauer, E. A., Binder-Scholl, G. K., Goloubeva, O. G., Vogl, D. T., Lacey, S. F., Badros, A. Z., Garfall, A. L., Weiss, B. M., Finklestein, J. M., et al. (2015) · Nature Medicine · doi:10.1038/nm.3910 · Cited by 857 · see citing works

Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production.

Leonard, J. P., Sherman, M. L., Fisher, G. L., Buchanan, L. J., Larsen, G., Atkins, M. B., Sosman, J. A., Dutcher, J. P., Vogelzang, N. J., & Ryan, J. L. (1997) · PubMed · Cited by 820 · see citing works

Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes

Caruana, I., Savoldo, B., Hoyos, V., Weber, G., Liu, H., Kim, E. S., Ittmann, M., Marchetti, D., & Dotti, G. (2015) · Nature Medicine · doi:10.1038/nm.3833 · Cited by 820 · see citing works

The cytoplasmic domain of the T cell receptor ζ chain is sufficient to couple to receptor-associated signal transduction pathways

Irving, B. A., & Weiss, A. (1991) · Cell · doi:10.1016/0092-8674(91)90314-o · Cited by 806 · see citing works

Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells

Gallina, G., Dolcetti, L., Serafini, P., Santo, C. D., Marigo, I., Colombo, M. P., Basso, G., Brombacher, F., Borrello, I., Zanovello, P., et al. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28828 · Cited by 792 · see citing works

Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease

Ellebrecht, C. T., Bhoj, V. G., Nace, A., Choi, E. J., Mao, X., Cho, M. J., Zenzo, G. D., Lanzavecchia, A., Seykora, J. T., Cotsarelis, G., et al. (2016) · Science · doi:10.1126/science.aaf6756 · Cited by 742 · see citing works

PD-1– and CTLA-4–Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy Responses

Fedorov, V. D., Themeli, M., & Sadelain, M. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006597 · Cited by 737 · see citing works

Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors

Roybal, K. T., Williams, J. Z., Morsut, L., Rupp, L. J., Kolinko, I., Choe, J. H., Walker, W. J., McNally, K. A., & Lim, W. A. (2016) · Cell · doi:10.1016/j.cell.2016.09.011 · Cited by 723 · see citing works

Stress, Inflammation, and Defense of Homeostasis

Chovatiya, R., & Medzhitov, R. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.03.030 · Cited by 704 · see citing works

Remote control of therapeutic T cells through a small molecule–gated chimeric receptor

Wu, C.-Y., Roybal, K. T., Puchner, E. M., Onuffer, J., & Lim, W. A. (2015) · Science · doi:10.1126/science.aab4077 · Cited by 692 · see citing works

Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning

Pegram, H. J., Lee, J., Hayman, E. G., Imperato, G. H., Tedder, T. F., Sadelain, M., & Brentjens, R. J. (2012) · Blood · doi:10.1182/blood-2011-12-400044 · Cited by 677 · see citing works

Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells

Imai, C., Iwamoto, S., & Campana, D. (2005) · Blood · doi:10.1182/blood-2004-12-4797 · Cited by 661 · see citing works

Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T Cells

Scholler, J., Brady, T., Binder-Scholl, G. K., Hwang, W., Plesa, G., Hege, K. M., Vogel, A. N., Kalos, M. D., Riley, J. L., Deeks, S. G., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003761 · Cited by 651 · see citing works

N OTCH AND P RESENILIN : Regulated Intramembrane Proteolysis Links Development and Degeneration

Selkoe, D. J., & Kopan, R. (2003) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.26.041002.131334 · Cited by 630 · see citing works

A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells

Wang, X., Chang, W.-C., Wong, C. W., Colcher, D. M., Sherman, M. A., Ostberg, J. R., Forman, S. J., Riddell, S. R., & Jensen, M. C. (2011) · Blood · doi:10.1182/blood-2011-02-337360 · Cited by 600 · see citing works

Engineering synthetic vaccines using cues from natural immunity

Irvine, D. J., Swartz, M. A., & Szeto, G. L. (2013) · Nature Materials · doi:10.1038/nmat3775 · Cited by 596 · see citing works

Distinct roles of IL-12 and IL-15 in human natural killer cell activation by dendritic cells from secondary lymphoid organs

Ferlazzo, G., Pack, M., Thomas, D. A., Paludan, C., Schmid, D., Strowig, T., Bougras-Cartron, G., Müller, W. A., Moretta, L., & Münz, C. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0407522101 · Cited by 583 · see citing works

T–cell mediated rejection of gene–modified HIV–specific cytotoxic T lymphocytes in HIV–infected patients

Riddell, S. R., Elliott, M., Lewinsohn, D. A., Gilbert, M. J., Wilson, L., Manley, S. A., Lupton, S. D., Overell, R. W., Reynolds, T. C., Corey, L., et al. (1996) · Nature Medicine · doi:10.1038/nm0296-216 · Cited by 564 · see citing works

Exploiting a natural conformational switch to engineer an interleukin-2 ‘superkine’

Levin, A. M., Bates, D. L., Ring, A. M., Krieg, C., Lin, J. T., Su, L., Moraga, I., Raeber, M. E., Bowman, G. R., Novick, P. A., et al. (2012) · Nature · doi:10.1038/nature10975 · Cited by 552 · see citing works

Chimeric Receptors Providing Both Primary and Costimulatory Signaling in T Cells from a Single Gene Product

Finney, H. M., Lawson, A. D. G., Bebbington, C. R., & Weir, A. N. C. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.6.2791 · Cited by 542 · see citing works

Expression of a Functional CCR2 Receptor Enhances Tumor Localization and Tumor Eradication by Retargeted Human T cells Expressing a Mesothelin-Specific Chimeric Antibody Receptor

Moon, E. K., Carpenito, C., Sun, J., Wang, L. S., Kapoor, V., Predina, J. D., Powell, D. J., Riley, J. L., June, C. H., & Albelda, S. Μ. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0351 · Cited by 537 · see citing works

T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model

Di Stasi, A., De Angelis, B., Rooney, C. M., Zhang, L., Mahendravada, A., Foster, A. E., Heslop, H. E., Brenner, M. K., Dotti, G., & Savoldo, B. (2009) · Blood · doi:10.1182/blood-2009-03-209650 · Cited by 533 · see citing works

Enhanced Tumor Trafficking of GD2 Chimeric Antigen Receptor T Cells by Expression of the Chemokine Receptor CCR2b

Craddock, J. A., Lu, A., Bear, A. S., Pulè, M. A., Brenner, M. K., Rooney, C. M., & Foster, A. E. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181ee6675 · Cited by 514 · see citing works

Immune Regulation of Metabolic Homeostasis in Health and Disease

Brestoff, J. R., & Artis, D. (2015) · Cell · doi:10.1016/j.cell.2015.02.022 · Cited by 498 · see citing works

Durability of Complete Responses in Patients With Metastatic Cancer Treated With High-Dose Interleukin-2

Rosenberg, S. A., Yang, J. C., White, D. E., & Steinberg, S. M. (1998) · Annals of Surgery · doi:10.1097/00000658-199809000-00004 · Cited by 486 · see citing works

Dual Targeting of ErbB2 and MUC1 in Breast Cancer Using Chimeric Antigen Receptors Engineered to Provide Complementary Signaling

Wilkie, S., van Schalkwyk, M. C., Hobbs, S., Davies, D. M., van der Stegen, S. J. C., Pereira, A. C. P., Burbridge, S. E., Box, C., Eccles, S. A., & Maher, J. F. (2012) · Journal of Clinical Immunology · doi:10.1007/s10875-012-9689-9 · Cited by 478 · see citing works

Adoptive Transfer of Autologous Natural Killer Cells Leads to High Levels of Circulating Natural Killer Cells but Does Not Mediate Tumor Regression

Parkhurst, M. R., Riley, J. P., Dudley, M. E., & Rosenberg, S. A. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1347 · Cited by 477 · see citing works

T-Cell and NK-Cell Infiltration into Solid Tumors: A Key Limiting Factor for Efficacious Cancer Immunotherapy

Melero, I., Rouzaut, A., Motz, G. T., & Coukos, G. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0985 · Cited by 439 · see citing works

Cell-Based Therapeutics: The Next Pillar of Medicine

Fischbach, M., Bluestone, J., & Lim, W. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005568 · Cited by 410 · see citing works

How viruses hijack cell regulation

Davey, N. E., Travé, G., & Gibson, T. J. (2010) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2010.10.002 · Cited by 383 · see citing works

Mechanical Allostery: Evidence for a Force Requirement in the Proteolytic Activation of Notch

Gordon, W. R., Zimmerman, B., He, L., Miles, L., Huang, J., Tiyanont, K., McArthur, D. G., Aster, J. C., Perrimon, N., Loparo, J. J., et al. (2015) · Developmental Cell · doi:10.1016/j.devcel.2015.05.004 · Cited by 374 · see citing works

Structural basis for autoinhibition of Notch

Gordon, W. R., Vardar‐Ulu, D., Histen, G., Sanchez-Irizarry, C., Aster, J. C., & Blacklow, S. C. (2007) · Nature Structural & Molecular Biology · doi:10.1038/nsmb1227 · Cited by 372 · see citing works

Prospects for gene-engineered T cell immunotherapy for solid cancers

Klebanoff, C. A., Rosenberg, S. A., & Restifo, N. P. (2016) · Nature Medicine · doi:10.1038/nm.4015 · Cited by 366 · see citing works

Chimeric Antigen Receptor Therapy for Cancer

Barrett, D. M., Singh, N., Porter, D. L., Grupp, S. A., & June, C. H. (2013) · Annual Review of Medicine · doi:10.1146/annurev-med-060512-150254 · Cited by 350 · see citing works

Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines.

Margolin, K. A., Rayner, A. A., Hawkins, M., Atkins, M. B., Dutcher, J. P., Fisher, R. I., Weiss, G. R., Doroshow, J. H., Jaffe, H. S., & Röper, M. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.4.486 · Cited by 346 · see citing works

Chimeric Antigen Receptor T Cells with Dissociated Signaling Domains Exhibit Focused Antitumor Activity with Reduced Potential for Toxicity In Vivo

Lanitis, E., Poussin, M., Klattenhoff, A. W., Song, D.-G., Sandaltzopoulos, R., June, C. H., & Powell, D. J. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0008 · Cited by 329 · see citing works

Insights into Cytokine–Receptor Interactions from Cytokine Engineering

Spangler, J. B., Moraga, I., Mendoza, J. L., & Garcia, K. C. (2015) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120211 · Cited by 304 · see citing works

Improving Adoptive T Cell Therapy by Targeting and Controlling IL-12 Expression to the Tumor Environment

Zhang, L., Kerkar, S. P., Yu, Z., Zheng, Z., Yang, S., Restifo, N. P., Rosenberg, S. A., & Morgan, R. A. (2011) · Molecular Therapy · doi:10.1038/mt.2010.313 · Cited by 293 · see citing works

Tailoring nanoparticle designs to target cancer based on tumor pathophysiology

Sykes, E. A., Dai, Q., Sarsons, C. D., Chen, J., Rocheleau, J. V., Hwang, D. M., Zheng, G., Cramb, D. T., Rinker, K. D., & Chan, W. C. W. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1521265113 · Cited by 280 · see citing works

Immunoengineering: How Nanotechnology Can Enhance Cancer Immunotherapy

Goldberg, M. S. (2015) · Cell · doi:10.1016/j.cell.2015.03.037 · Cited by 279 · see citing works

Engineering GPCR signaling pathways with RASSLs

Conklin, B. R., Hsiao, E. C., Claeysen, S., Dumuis, A., Srinivasan, S., Forsayeth, J., Guettier, J., Chang, W. C., Pei, Y., McCarthy, K. D., et al. (2008) · Nature Methods · doi:10.1038/nmeth.1232 · Cited by 256 · see citing works

Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts

Kerkar, S. P., Muranski, P. J., Kaiser, A., Boni, A., Sanchez-Perez, L. A., Yu, Z., Palmer, D. C., Reger, R. N., Borman, Z. A., Zhang, L., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0735 · Cited by 254 · see citing works

Natural killer cell memory

Paust, S., & von Andrian, U. H. (2011) · Nature Immunology · doi:10.1038/ni.2032 · Cited by 236 · see citing works

Managing toxicities of high-dose interleukin-2.

Schwartz, R. N., Stover, L. L., & Dutcher, J. P. (2002) · PubMed · Cited by 235 · see citing works

Rapamycin Analogs with Differential Binding Specificity Permit Orthogonal Control of Protein Activity

Bayle, J. H., Grimley, J. S., Stankunas, K., Gestwicki, J. E., Wandless, T. J., & Crabtree, G. R. (2006) · Chemistry & Biology · doi:10.1016/j.chembiol.2005.10.017 · Cited by 211 · see citing works

2B4 (CD244) Signaling by Recombinant Antigen-specific Chimeric Receptors Costimulates Natural Killer Cell Activation to Leukemia and Neuroblastoma Cells

Altvater, B., Landmeier, S., Pscherer, S., Temme, J., Schweer, K., Kailayangiri, S., Campana, D., Juergens, H., Pulè, M. A., & Rössig, C. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2810 · Cited by 207 · see citing works

Levels of peripheral CD4+FoxP3+ regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer

Yao, X., Ahmadzadeh, M., Lu, Y., Liewehr, D. J., Dudley, M. E., Liu, F., Schrump, D. S., Steinberg, S. M., Rosenberg, S. A., & Robbins, P. F. (2012) · Blood · doi:10.1182/blood-2011-10-386482 · Cited by 206 · see citing works

Cutting Edge: Murine Dendritic Cells Require IL-15Rα to Prime NK Cells

Koka, R. M., Burkett, P. R., Chien, M., Chai, S., Boone, D. L., & Ma, A. I. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.6.3594 · Cited by 201 · see citing works

Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas

Kruschinski, A., Moosmann, A., Poschke, I. C., Norell, H., Chmielewski, M. M., Seliger, B., Kiessling, R. W., Blankenstein, T. J. F., Abken, H., & Charo, J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804788105 · Cited by 196 · see citing works

Interleukin-2 Activity Can Be Fine Tuned with Engineered Receptor Signaling Clamps

Mitra, S., Ring, A. M., Amarnath, S., Spangler, J. B., Li, P., Ju, W., Fischer, S., Oh, J., Spolski, R. J., Weiskopf, K., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.04.018 · Cited by 175 · see citing works

A clinically adaptable method to enhance the cytotoxicity of natural killer cells against B-cell malignancies

Shimasaki, N., Fujisaki, H., Cho, D., Masselli, M., Lockey, T. D., Eldridge, P. W., Leung, W. H., & Campana, D. (2012) · Cytotherapy · doi:10.3109/14653249.2012.671519 · Cited by 174 · see citing works

A Tet-On Inducible System for Controlling CD19-Chimeric Antigen Receptor Expression upon Drug Administration

Sakemura, R. L., Terakura, S., Watanabe, K., Julamanee, J., Takagi, E., Miyao, K., Koyama, D., Goto, T., Hanajiri, R., Nishida, T., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0043 · Cited by 164 · see citing works

Targeting CD20+ Aggressive B-cell Non–Hodgkin Lymphoma by Anti-CD20 CAR mRNA-Modified Expanded Natural Killer Cells In Vitro and in NSG Mice

Chu, Y., Hochberg, J., Yahr, A., Ayello, J., van de Ven, C., Barth, M., Czuczman, M., & Cairo, M. (2014) · Cancer immunology research · doi:10.1158/2326-6066.cir-14-0114 · Cited by 157 · see citing works

The Utility of Paradoxical Components in Biological Circuits

Hart, Y., & Alon, U. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.01.004 · Cited by 151 · see citing works

Therapeutic Potential of T Cell Chimeric Antigen Receptors (CARs) in Cancer Treatment: Counteracting Off-Tumor Toxicities for Safe CAR T Cell Therapy

Gross, G., & Eshhar, Z. (2016) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010814-124844 · Cited by 147 · see citing works

Expression of chimeric antigen receptors in natural killer cells with a regulatory-compliant non-viral method

Li, L., Liu, L. N., Feller, S., Allen, C., Shivakumar, R., Fratantoni, J. C., Wolfraim, L. A., Fujisaki, H., Campana, D., Chopas, N., et al. (2009) · Cancer Gene Therapy · doi:10.1038/cgt.2009.61 · Cited by 143 · see citing works

FOXP3 expression accurately defines the population of intratumoral regulatory T cells that selectively accumulate in metastatic melanoma lesions

Ahmadzadeh, M., Felipe-Silva, A., Heemskerk, B., Powell, D. J., Wunderlich, J. R., Merino, M. J., & Rosenberg, S. A. (2008) · Blood · doi:10.1182/blood-2008-06-163048 · Cited by 139 · see citing works

The expanding universe of transposon technologies for gene and cell engineering

Ivics, Z., & Izsvák, Z. (2010) · Mobile DNA · doi:10.1186/1759-8753-1-25 · Cited by 130 · see citing works

The microanatomy of T‐cell responses

Lämmermann, T., & Sixt, M. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00592.x · Cited by 126 · see citing works

Increased Circulating Nitrogen Oxides After Human Tumor Immunotherapy: Correlation With Toxic Hemodynamic Changes

Ochoa, J. B., Curti, B. D., Peitzman, A. B., Simmons, R. L., Billiar, T. R., Hoffman, R. P., Rault, R., Longo, D., Urba, W. J., & Ochoa, A. C. (1992) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/84.11.864 · Cited by 125 · see citing works

Improving the safety of cell therapy with the TK-suicide gene

Greco, R., Oliveira, G., Stanghellini, M. T. L., Vago, L., Bondanza, A., Peccatori, J., Cieri, N., Marktel, S., Mastaglio, S., Bordignon, C., et al. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00095 · Cited by 116 · see citing works

Optimization of the PiggyBac Transposon System for the Sustained Genetic Modification of Human T Lymphocytes

Nakazawa, Y., Huye, L. E., Dotti, G., Foster, A. E., Vera, J. F., Manuri, P. R., June, C. H., Rooney, C. M., & Wilson, M. H. (2009) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181ad762b · Cited by 113 · see citing works

Identification of New Melanoma Epitopes on Melanosomal Proteins Recognized by Tumor Infiltrating T Lymphocytes Restricted by HLA-A1, -A2, and -A3 Alleles

Kawakami, Y., Robbins, P. F., Wang, X., Tupesis, J. P., Parkhurst, M. R., Kang, X., Sakaguchi, K., Appella, E., & Rosenberg, S. A. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.12.6985 · Cited by 113 · see citing works

Paradoxical Signaling by a Secreted Molecule Leads to Homeostasis of Cell Levels

Hart, Y., Reich-Zeliger, S., Antebi, Y. E., Zaretsky, I., Mayo, A., Alon, U. S., & Friedman, N. (2014) · Cell · doi:10.1016/j.cell.2014.07.033 · Cited by 106 · see citing works

Synthetic control of mammalian-cell motility by engineering chemotaxis to an orthogonal bioinert chemical signal

Park, J. S., Rhau, B., Hermann, A., McNally, K. A., Zhou, C., Gong, D., Weiner, O. D., Conklin, B. R., Onuffer, J., & Lim, W. A. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1402087111 · Cited by 103 · see citing works

Challenges and opportunities of allogeneic donor-derived CAR T cells

Yang, Y., Jacoby, E., & Fry, T. J. (2015) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000181 · Cited by 101 · see citing works

Myeloid Cells Obtained from the Blood but Not from the Tumor Can Suppress T-cell Proliferation in Patients with Melanoma

Gros, A., Turcotte, S., Wunderlich, J. R., Ahmadzadeh, M., Dudley, M. E., & Rosenberg, S. A. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1108 · Cited by 86 · see citing works

Design of chimeric antigen receptors with integrated controllable transient functions

Juillerat, A., Maréchal, A., Filhol, J.-M., Valton, J., Duclert, A., Poirot, L., & Duchateau, P. N. (2016) · Scientific Reports · doi:10.1038/srep18950 · Cited by 85 · see citing works

TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor Milieu

Kunert, A., Straetemans, T., Govers, C., Lamers, C., Mathijssen, R. H. J., Sleijfer, S., & Debets, R. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00363 · Cited by 77 · see citing works

Tumor cells escape suicide gene therapy by genetic and epigenetic instability

Frank, O. (2004) · Blood · doi:10.1182/blood-2004-03-0852 · Cited by 57 · see citing works

A composite MyD88/CD40 switch synergistically activates mouse and human dendritic cells for enhanced antitumor efficacy

Narayanan, P., Lapteva, N., Seethammagari, M. R., Levitt, J. M., Slawin, K. M., & Spencer, D. M. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44327 · Cited by 55 · see citing works

Synthetic immunology: modulating the human immune system

Geering, B., & Fussenegger, M. (2014) · Trends in biotechnology · doi:10.1016/j.tibtech.2014.10.006 · Cited by 46 · see citing works

Evaluation of γ-Retroviral Vectors That Mediate the Inducible Expression of IL-12 for Clinical Application

Zhang, L., Feldman, S. A., Zheng, Z., Chinnasamy, N., Xu, H., Nahvi, A. V., Dudley, M. E., Rosenberg, S. A., & Morgan, R. A. (2012) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31825898e8 · Cited by 33 · see citing works

Grand Challenge Commentary: Synthetic immunology to engineer human immunity

Spiegel, D. A. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.477 · Cited by 27 · see citing works

Engineering cytokine receptors to control cellular functions

Kawahara, M., Ueda, H., & Nagamune, T. (2009) · Biochemical Engineering Journal · doi:10.1016/j.bej.2009.09.010 · Cited by 24 · see citing works

Selective expansion of genetically modified T cells using an antibody/interleukin-2 receptor chimera

Sogo, T., Kawahara, M., Tsumoto, K., Kumagai, I., Ueda, H., & Nagamune, T. (2008) · Journal of Immunological Methods · doi:10.1016/j.jim.2008.05.003 · Cited by 16 · see citing works

Tumour-intrinsic resistance to immune checkpoint blockade

Kalbasi, A. K., & Ribas, A. (2019) · Nature reviews. Immunology · doi:10.1038/s41577-019-0218-4 · Cited by 1,491 · see citing works

Reprogramming human T cell function and specificity with non-viral genome targeting

Roth, T. L., Puig-Saus, C., Yu, R., Shifrut, E., Carnevale, J., Li, P. J., Hiatt, J., Saco, J., Krystofinski, P., Li, H., et al. (2018) · Nature · doi:10.1038/s41586-018-0326-5 · Cited by 839 · see citing works

Engineering the next generation of cell-based therapeutics

Bashor, C. J., Hilton, I. B., Bandukwala, H. S., Smith, D. M., & Omid Veiseh, A. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00476-6 · Cited by 448 · see citing works

Engineering living therapeutics with synthetic biology

Cubillos-Ruiz, A., Guo, T., Sokolovska, A., Miller, P., Collins, J. J., Lu, T. K., & Lora, J. M. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00285-3 · Cited by 371 · see citing works

T cell receptor‐based cancer immunotherapy: Emerging efficacy and pathways of resistance

Chandran, S. S., & Klebanoff, C. A. (2019) · Immunological Reviews · doi:10.1111/imr.12772 · Cited by 325 · see citing works

Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward

Li, J., Li, W., Huang, K., Zhang, Y., Kupfer, G. M., & Zhao, Q. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0568-6 · Cited by 245 · see citing works

A Deep Neural Network for Predicting and Engineering Alternative Polyadenylation

Bogard, N., Linder, J., Rosenberg, A. B., & Seelig, G. (2019) · Cell · doi:10.1016/j.cell.2019.04.046 · Cited by 215 · see citing works

A genome-scale gain-of-function CRISPR screen in CD8 T cells identifies proline metabolism as a means to enhance CAR-T therapy

Ye, L., Park, J. J.-Y., Peng, L., Yang, Q., Chow, R. D.-W., Dong, M. B., Lam, S. Z., Guo, J., Tang, E., Zhang, Y., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.02.009 · Cited by 204 · see citing works

Computational strategies for dissecting the high-dimensional complexity of adaptive immune repertoires

Miho, E., Yermanos, A., Weber, C. R., Berger, C. T., Reddy, S. T., & Greiff, V. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00224 · Cited by 189 · see citing works

Targeting public neoantigens for cancer immunotherapy

Pearlman, A. H., Hwang, M. S., Konig, M. F., Hsiue, E. H.-C., Douglass, J., DiNapoli, S. R., Mog, B. J., Bettegowda, C., Pardoll, D. M., Gabelli, S. B., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00210-y · Cited by 192 · see citing works

A small and highly sensitive red/far-red optogenetic switch for applications in mammals

Zhou, Y., Kong, D., Wang, X., Yu, G., Wu, X., Guan, N., Weber, W., & Ye, H. (2021) · Nature Biotechnology · doi:10.1038/s41587-021-01036-w · Cited by 154 · see citing works

Target Reprogramming Lysosomes of CD8+ T Cells by a Mineralized Metal–Organic Framework for Cancer Immunotherapy

Zhao, Q. P., Gong, Z., Li, Z., Wang, J., Zhang, J., Zhao, Z., Zhang, P., Zheng, S., Miron, R. J., Yuan, Q., et al. (2021) · Advanced Materials · doi:10.1002/adma.202100616 · Cited by 146 · see citing works

Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide

Jan, M., Sperling, A. S., & Ebert, B. L. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00479-z · Cited by 137 · see citing works

Principles of Immunotherapy: Implications for Treatment Strategies in Cancer and Infectious Diseases

Naran, K., Nundalall, T., Chetty, S., & Barth, S. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.03158 · Cited by 123 · see citing works

Regulated Expansion and Survival of Chimeric Antigen Receptor-Modified T Cells Using Small Molecule-Dependent Inducible MyD88/CD40

Foster, A. E., Mahendravada, A., Shinners, N. P., Chang, W.-C., Crisostomo, J., Lu, A., Khalil, M., Morschl, É., Shaw, J. L., Saha, S., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.06.014 · Cited by 106 · see citing works

A new era of cancer immunotherapy: combining revolutionary technologies for enhanced CAR-M therapy

Li, N., Geng, S., Dong, Z., Jin, Y., Ying, H., Li, H., & Shi, L. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02032-9 · Cited by 104 · see citing works

Light‐Controlled Mammalian Cells and Their Therapeutic Applications in Synthetic Biology

Mansouri, M., Strittmatter, T., & Fussenegger, M. (2018) · Advanced Science · doi:10.1002/advs.201800952 · Cited by 92 · see citing works

B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma

Tai, Y., & Anderson, K. C. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1641196 · Cited by 93 · see citing works

Engineering advanced cancer therapies with synthetic biology

Wu, M.-R., Jusiak, B., & Lu, T. K. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0121-0 · Cited by 90 · see citing works

High-throughput antibody engineering in mammalian cells by CRISPR/Cas9-mediated homology-directed mutagenesis

Mason, D. M., Weber, C. R., Parola, C., Meng, S. M., Greiff, V., Kelton, W., & Reddy, S. T. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky550 · Cited by 83 · see citing works

Synthetic Switches and Regulatory Circuits in Plants

Andres, J., Blomeier, T., & Zurbriggen, M. D. (2019) · PLANT PHYSIOLOGY · doi:10.1104/pp.18.01362 · Cited by 80 · see citing works

Multiscale engineering of immune cells and lymphoid organs

Kim, S., Shah, S. B., Graney, P. L., & Singh, A. (2019) · Nature Reviews Materials · doi:10.1038/s41578-019-0100-9 · Cited by 79 · see citing works

Chimeric antigen receptor- and natural killer cell receptor-engineered innate killer cells in cancer immunotherapy

Zhang, C., Hu, Y., Xiao, W., & Tian, Z. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-021-00732-6 · Cited by 80 · see citing works

Next Generation CAR T Cells for the Immunotherapy of High-Grade Glioma

Petersen, C. T., & Krenciute, G. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00069 · Cited by 82 · see citing works

Engineering cell–cell communication networks: programming multicellular behaviors

Toda, S., Frankel, N. W., & Lim, W. A. (2019) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2019.04.020 · Cited by 79 · see citing works

Logic-gated and contextual control of immunotherapy for solid tumors: contrasting multi-specific T cell engagers and CAR-T cell therapies

Nolan-Stevaux, O., & Smith, R. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1490911 · Cited by 78 · see citing works

A green tea–triggered genetic control system for treating diabetes in mice and monkeys

Yin, J., Yang, L., Mou, L., Dong, K., Jiang, J. D., Xue, S., Xu, Y. C., Wang, X., Lu, Y., & Ye, H. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav8826 · Cited by 74 · see citing works

Discovery and validation of human genomic safe harbor sites for gene and cell therapies

Aznauryan, E. I., Yermanos, A., Kinzina, E., Devaux, A., Kapetanovic, E., Milanova, D., Church, G. M., & Reddy, S. T. (2022) · Cell Reports Methods · doi:10.1016/j.crmeth.2021.100154 · Cited by 73 · see citing works

Engineering synthetic suppressor T cells that execute locally targeted immunoprotective programs

Reddy, N. R., Maachi, H., Xiao, Y., Simic, M., Yu, W., Tonai, Y., Cabanillas, D. A., Serrano-Wu, E. M., Pauerstein, P. T., Tamaki, W., et al. (2024) · Science · doi:10.1126/science.adl4793 · Cited by 68 · see citing works

Engineering multicellular systems: Using synthetic biology to control tissue self-organization

Johnson, M. B., March, A. R., & Morsut, L. (2017) · Current Opinion in Biomedical Engineering · doi:10.1016/j.cobme.2017.10.008 · Cited by 61 · see citing works

Emerging CAR T Cell Strategies for the Treatment of AML

Vishwasrao, P., Li, G., Boucher, J. C., Smith, D. L., & Hui, S. K. (2022) · Cancers · doi:10.3390/cancers14051241 · Cited by 59 · see citing works

CRISPR-Based Tools in Immunity

Simeonov, D. R., & Marson, A. (2019) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042718-041522 · Cited by 56 · see citing works

Chimeric Antigen Receptor T-Cell Therapy in Metastatic Castrate-Resistant Prostate Cancer

Perera, O. M., Thomas, P. B., Risbridger, G. P., Taylor, R. A., Azad, A., Hofman, M. S., Williams, E. D., & Vela, I. (2022) · Cancers · doi:10.3390/cancers14030503 · Cited by 54 · see citing works

Therapeutic cell engineering: designing programmable synthetic genetic circuits in mammalian cells

Mansouri, M., & Fussenegger, M. (2021) · Protein & Cell · doi:10.1007/s13238-021-00876-1 · Cited by 52 · see citing works

Recent Advances in Polymeric Nanomedicines for Cancer Immunotherapy

Lee, E. S., Shin, J. M., Son, S., Ko, H., Um, W., Song, S. H., Lee, J. A., & Park, J. H. (2019) · Advanced Healthcare Materials · doi:10.1002/adhm.201801320 · Cited by 51 · see citing works

Engineering genetic devices for in vivo control of therapeutic T cell activity triggered by the dietary molecule resveratrol

Yang, L., Yin, J., Wu, J., Qiao, L., Zhao, E. M., Cai, F., & Ye, H. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2106612118 · Cited by 50 · see citing works

helixCAM: A platform for programmable cellular assembly in bacteria and human cells

Chao, G., Wannier, T. M., Gutierrez, C. S., Borders, N. C., Appleton, E., Chadha, A., Lebar, T., & Church, G. M. (2022) · Cell · doi:10.1016/j.cell.2022.08.012 · Cited by 47 · see citing works

Newly identified T cell subsets in mechanistic studies of food immunotherapy

Sampath, V., & Nadeau, K. C. (2019) · Journal of Clinical Investigation · doi:10.1172/jci124605 · Cited by 47 · see citing works

Exosomes: Powerful weapon for cancer nano-immunoengineering

Pi, Y., Xia, B.-R., Jin, M., Jin, W., & Lou, G. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114487 · Cited by 41 · see citing works

New directions in chimeric antigen receptor T cell [CAR‐T] therapy and related flow cytometry

Maryamchik, E., Gallagher, K., Preffer, F. I., Kadauke, S., & Maus, M. V. (2020) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.21880 · Cited by 41 · see citing works

Genetic engineering of regulatory T cells for treatment of autoimmune disorders including type 1 diabetes

Tuomela, K., & Levings, M. K. (2024) · Diabetologia · doi:10.1007/s00125-023-06076-2 · Cited by 38 · see citing works

Multidomain Control Over TEC Kinase Activation State Tunes the T Cell Response

Andreotti, A. H., Joseph, R. E., Conley, J. M., Iwasa, J., & Berg, L. J. (2018) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042617-053344 · Cited by 38 · see citing works

Using machine learning to enhance and accelerate synthetic biology

Rai, K., Wang, Y., O’Connell, R. W., Patel, A. B., & Bashor, C. J. (2024) · Current Opinion in Biomedical Engineering · doi:10.1016/j.cobme.2024.100553 · Cited by 31 · see citing works

Immune Cell‐Based Microrobots for Remote Magnetic Actuation, Antitumor Activity, and Medical Imaging

Dogan, N. O., Suadiye, E., Wrede, P., Lazović, J., Dayan, C. B., Soon, R. H., Aghakhani, A., Richter, G., & Sitti, M. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202400711 · Cited by 31 · see citing works

The Landscape of CAR T Cells Beyond Acute Lymphoblastic Leukemia for Pediatric Solid Tumors

DeRenzo, C. C., Krenciute, G., & Gottschalk, S. M. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_200773 · Cited by 32 · see citing works

Derivation of mimetic γδ T cells endowed with cancer recognition receptors from reprogrammed γδ T cell

Zeng, J., Tang, S. Y., & Wang, S. (2019) · PLoS ONE · doi:10.1371/journal.pone.0216815 · Cited by 31 · see citing works

Elucidation and refinement of synthetic receptor mechanisms

Edelstein, H. I., Donahue, P. S., Muldoon, J. J., Kang, A. K., Dolberg, T. B., Battaglia, L. M., Allchin, E. R., Hong, M., & Leonard, J. N. (2020) · Synthetic Biology · doi:10.1093/synbio/ysaa017 · Cited by 31 · see citing works

Chimeric Antigen Receptors Based on Low Affinity Mutants of FcεRI Re-direct T Cell Specificity to Cells Expressing Membrane IgE

Ward, D. E., Fay, B. L., Adejuwon, A. O., Han, H., & Ma, Z. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02231 · Cited by 30 · see citing works

Electrogenetics: Bridging synthetic biology and electronics to remotely control the behavior of mammalian designer cells

Mansouri, M., & Fussenegger, M. (2022) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2022.102151 · Cited by 29 · see citing works

Exploiting B Cell Transfer for Cancer Therapy: Engineered B Cells to Eradicate Tumors

Page, A., Hubert, J., Fusil, F., & Cosset, F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189991 · Cited by 29 · see citing works

Guiding regulatory T cells to the allograft

Lamarche, C., & Levings, M. K. (2017) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000000483 · Cited by 27 · see citing works

Graft Versus Leukemia: Current Status and Future Perspectives

O'Neill, A. T., & Chakraverty, R. K. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.01801 · Cited by 26 · see citing works

Emerging Novel Combined CAR-T Cell Therapies

Nguyen, T. A., Johanning, G. L., & Shi, Y. H. (2022) · Cancers · doi:10.3390/cancers14061403 · Cited by 26 · see citing works

Cell-Selective Multifunctional Surface Covalent Reconfiguration Using Aptamer-Enabled Proximity Catalytic Labeling

Guo, Y., Wang, N., Zhong, Y., Li, W., Li, Y., Wang, G., Yao, Y., Shi, Y., Chen, L., Wang, X., et al. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.2c11150 · Cited by 24 · see citing works

Engineering T Cells to Treat Cancer: The Convergence of Immuno-Oncology and Synthetic Biology

Choe, J. H., Williams, J. Z., & Lim, W. A. (2020) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030419-033657 · Cited by 23 · see citing works

Synthetic receptors for logic gated T cell recognition and function

Simon, S., Bugos, G., Salter, A. I., & Riddell, S. R. (2021) · Current Opinion in Immunology · doi:10.1016/j.coi.2021.09.003 · Cited by 22 · see citing works

Recent advances in developing and applying biosensors for synthetic biology

Jones, K. A., Zinkus-Boltz, J., & Dickinson, B. C. (2019) · Nano Futures · doi:10.1088/2399-1984/ab4b78 · Cited by 19 · see citing works

Toward Tightly Tuned Gene Expression Following Lentiviral Vector Transduction

Page, A., Fusil, F., & Cosset, F. (2020) · Viruses · doi:10.3390/v12121427 · Cited by 19 · see citing works

Nanoscale programming of cellular and physiological phenotypes: inorganic meets organic programming

Dokholyan, N. V. (2021) · npj Systems Biology and Applications · doi:10.1038/s41540-021-00176-8 · Cited by 16 · see citing works

Synthetic biology-based optogenetic approaches to control therapeutic designer cells

Mansouri, M., & Fussenegger, M. (2021) · Current Opinion in Systems Biology · doi:10.1016/j.coisb.2021.100396 · Cited by 18 · see citing works

CAR-T cells for cancer immunotherapy

Xie, Y., Li, X., Wu, J., Zeng, H., Boucetta, H., Wang, B., Yang, P., & He, W. (2023) · Chinese Chemical Letters · doi:10.1016/j.cclet.2023.108202 · Cited by 18 · see citing works

Allo Beta Cell transplantation: specific features, unanswered questions, and immunological challenge

Caldara, R., Tomajer, V., Monti, P., Sordi, V., Citro, A., Chimienti, R., Gremizzi, C., Catarinella, D., Tentori, S., Paloschi, V., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1323439 · Cited by 19 · see citing works

Transformation of Receptor Tyrosine Kinases into Glutamate Receptors and Photoreceptors

Leippe, P., Broichhagen, J., Cailliau, K., Mougel, A., Morel, M., Dissous, C., Trauner, D. H., & Vicogne, J. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201915352 · Cited by 17 · see citing works

Cell-based immunotherapy in gynecologic malignancies

Schaar, B. T., Krishnan, V., Tallapragada, S., & Dorigo, O. (2017) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000000433 · Cited by 17 · see citing works

Ectopic activation of the miR-200c–EpCAM axis enhances antitumor T cell responses in models of adoptive cell therapy

Zhang, M., Zhao, Z., Pritykin, Y., Hannum, M., Scott, A., Kuo, F., Sanghvi, V. R., Chan, T. A.-T., Seshan, V., Wendel, H., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abg4328 · Cited by 14 · see citing works

AI and ML for Development of Cell and Gene Therapy for Personalized Treatment

Mhatre, S., Shukla, S., Chavda, V. P., Gandikota, L., & Patravale, V. B. (2023) · Wiley eBooks · doi:10.1002/9781119865728.ch16 · Cited by 14 · see citing works

Engineering Microorganisms for Cancer Immunotherapy

Liu, D., Yu, L., Rong, H., Liu, L., & Yin, J. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202304649 · Cited by 13 · see citing works

Advances in Synthetic Immunology for Targeted Treatment of Systemic Autoimmune Diseases: Opportunities, Challenges, and Future Directions

Adytia, G. J., Sutanto, H., Pratiwi, L., & Fetarayani, D. (2025) · Immuno · doi:10.3390/immuno5010006 · Cited by 13 · see citing works

Multigene delivery in mammalian cells: Recent advances and applications

Mansouri, M., & Berger, P. (2018) · Biotechnology Advances · doi:10.1016/j.biotechadv.2018.01.012 · Cited by 13 · see citing works

Antibody-Recruiting Small Molecules: Synthetic Constructs as Immunotherapeutics

McEnaney, P. J., Parker, C. G., & Zhang, A. X. (2017) · Annual reports in medicinal chemistry · doi:10.1016/bs.armc.2017.08.008 · Cited by 11 · see citing works

Safety Strategies of Genetically Engineered T Cells in Cancer Immunotherapy

Ren, Y., Sun, S., & Han, S. (2017) · Current Pharmaceutical Design · doi:10.2174/1381612824666171227222624 · Cited by 11 · see citing works

Tumor‐Associated Macrophages as Therapeutic Targets: Deciphering Interaction Networks and Advancing Clinical Translation

Bao, W., Qu, X., Wang, Y., Huang, D. Y., Zhang, H., Dong, M., Sun, H., Yang, Z., & Li, X. (2026) · MedComm · doi:10.1002/mco2.70599 · Cited by 11 · see citing works

Synthetic Cells and Molecules in Cellular Immunotherapy

Lin, H., Li, C., Zhang, W., Wu, B., Wang, Y., Wang, S., Wang, D., Li, X., & Huang, H. (2024) · International Journal of Biological Sciences · doi:10.7150/ijbs.94346 · Cited by 10 · see citing works

Engineering combinatorial and dynamic decoders using synthetic immediate-early genes

Ravindran, P. T., Wilson, M. Z., Jena, S. G., & Toettcher, J. E. (2020) · Communications Biology · doi:10.1038/s42003-020-01171-1 · Cited by 10 · see citing works

Advances in Chimeric Antigen Receptor (CAR) T-Cell Therapies for the Treatment of Primary Brain Tumors

Mount, C., & Castro, L. N. G. (2022) · Antibodies · doi:10.3390/antib11020031 · Cited by 10 · see citing works

Current and future perspectives of chimeric antigen receptors against glioblastoma

Zhang, J., & Siller‐Farfán, J. A. (2022) · Immunotherapy Advances · doi:10.1093/immadv/ltac014 · Cited by 10 · see citing works

Engineered Th17 Cell Differentiation Using a Photoactivatable Immune Modulator

Parasar, B., & Chang, P. V. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.0c07485 · Cited by 9 · see citing works

Compact Programmable Control of Protein Secretion in Mammalian CellsPreprint

Vlahos, A. E., Call, C. C., Kadaba, S. E., Guo, S., & Gao, X. J. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.10.04.560774 · Cited by 8 · see citing works

Protein Engineering Paving the Way for Next-Generation Therapies in Cancer

Naderiyan, Z., & Shoari, A. (2025) · International Journal of Translational Medicine · doi:10.3390/ijtm5030028 · Cited by 7 · see citing works

Pro- and anti-apoptotic fate decisions induced by di- and trimeric synthetic cytokine receptors

Moßner, S., Floss, D. M., & Scheller, J. (2021) · iScience · doi:10.1016/j.isci.2021.102471 · Cited by 7 · see citing works

Regulatory T cell dysfunction and immunotherapeutic breakthroughs in type 1 diabetes

Zhou, K.-J., Rong, S.-J., Liu, Y.-C., Sun, F., Wang, T., Yu, Q.-L., & Wang, C.-Y. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1740102 · Cited by 6 · see citing works

Regulatable assembly of synthetic microtubule architectures using engineered microtubule-associated protein-IDR condensates

Chang, C., & Coyle, S. M. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.107544 · Cited by 6 · see citing works

Engineering B cells with customized therapeutic responses using a synthetic circuit

Page, A., Delles, M., Négre, D., Costa, C., Fusil, F., & Cosset, F. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.05.024 · Cited by 6 · see citing works

Synthetic Biology Approaches in Immunology

Mohammad, N. B., Lam, C. C. K., & Truong, K. (2018) · Biochemistry · doi:10.1021/acs.biochem.8b01081 · Cited by 6 · see citing works

Beyond borders: engineering organ-targeted immunotherapies to overcome site-specific barriers in cancer

Moorthy, T., Yalamandala, B. N., Huynh, T. M. H., Lien, H., Pan, W.-C., Iao, H. M., Chang, Y., & Hu, S. (2025) · Drug Delivery and Translational Research · doi:10.1007/s13346-025-01935-4 · Cited by 5 · see citing works

The Scope and Applications of Nature-Inspired Computing in Bioinformatics

Qazi, W., Qazi, S., Iqbal, N., & Raza, K. (2022) · Studies in computational intelligence · doi:10.1007/978-981-19-6379-7_1 · Cited by 5 · see citing works

Synthetic Immunotherapy: Programming Immune Cells with Novel and Sophisticated Logic Capabilities

Lam, C. K., Hyde, R. K., & Patel, S. A. (2022) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2022.06.001 · Cited by 5 · see citing works

Toward the clinical development of synthetic immunity to cancer

Garcia, J. M., Burnett, C. E., & Roybal, K. T. (2023) · Immunological Reviews · doi:10.1111/imr.13245 · Cited by 7 · see citing works

Bioinformatic Approaches to Validation and Functional Analysis of 3D Lung Cancer Models

Li, P. J., Roose, J. P., Jablons, D. M., & Kratz, J. R. (2021) · Cancers · doi:10.3390/cancers13040701 · Cited by 5 · see citing works

Decoding signaling architectures: CAR versus TCR dynamics in solid tumor immunotherapy

Chen, Z., & Zhou, X. (2025) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2025190 · Cited by 4 · see citing works

CAR‐DC combined with CAR‐T therapy for relapsed/refractory acute myeloid leukaemia: Research progress and future perspectives

Zhang, R., Zhang, J., Zhang, H., & Zhao, M. (2025) · Clinical and Translational Medicine · doi:10.1002/ctm2.70536 · Cited by 4 · see citing works

Design and mathematical analysis of activating transcriptional amplifiers that enable modular temporal control in synthetic juxtacrine circuits

Lam, C. K. (2023) · Synthetic and Systems Biotechnology · doi:10.1016/j.synbio.2023.09.008 · Cited by 4 · see citing works

iPSC-derived polyvalent vaccines as ontogenetically informed immunogens toward overcoming immune refractoriness in microsatellite-stable colorectal cancer: An emerging frontier in cancer immunotherapy

Kumar, A., Dwivedi, D., Ghosh, N., Gopalakrishnan, K., Rahamathulla, M., Ahmed, M. M., Nair, C., Singh, D., Singh, R., & Das, U. (2026) · Molecular Immunology · doi:10.1016/j.molimm.2026.08.008 · Cited by 3 · see citing works

Synthetic receptors in medicine

Mishra, S., Raval, M., Singh, V., & Tiwari, A. K. (2022) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2022.09.011 · Cited by 3 · see citing works

Beyond natural biology: rewiring cellular networks to study innate immunity

Landau, L. M., & Kagan, J. C. (2023) · Current Opinion in Immunology · doi:10.1016/j.coi.2023.102349 · Cited by 3 · see citing works

Gene Therapy Approaches in HIV Treatment

Kothawade, S. N., Wagh, V. S., Pande, V. V., & Lunkad, A. S. (2024) · Infectious diseases · doi:10.5772/intechopen.112138 · Cited by 3 · see citing works

Leveraging microRNAs for cellular therapy

Hasiuk, M., Dölz, M., Marone, R., & Jeker, L. T. (2023) · Immunology Letters · doi:10.1016/j.imlet.2023.08.005 · Cited by 3 · see citing works

Designer cell therapy for tissue regeneration

Zama, N., & Toda, S. (2024) · Inflammation and Regeneration · doi:10.1186/s41232-024-00327-4 · Cited by 2 · see citing works

Opportunities for artificial intelligence and synthetic biology in designing living drug delivery systems

Yang, J. H., & Bashor, C. J. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115883 · Cited by 2 · see citing works

CAR-M Therapy: From Concept to Clinical Translation in Solid Tumors

Miao, C., Chen, Z., Chen, J. K., Sun, J., Sun, Y., Shi, W., Xu, W., Li, Y., & Zhao, X. (2026) · Cells · doi:10.3390/cells15121113 · Cited by 2 · see citing works

Synthetic Biology Approaches in Immunology

Mohammad, N. B., Lam, C. C. K., & Truong, K. (2018) · Biochemistry · doi:10.1021/acs.biochem.8b01081 · Cited by 6 · see citing works

Systems-synthetic biology in understanding the complexities and simple devices in immunology

Soni, B., Nimsarkar, P., Mol, M., Saha, B., & Singh, S. (2018) · Cytokine · doi:10.1016/j.cyto.2018.03.029 · Cited by 4 · see citing works

Synthetic biology-engineered immunotherapies: Precision control of immune responses

Wang, Z., Fu, W., Ding, Y.-F., Gao, C.-C., Qin, H.-Y., & Zhao, J.-L. (2026) · Biotechnology Advances · doi:10.1016/j.biotechadv.2026.108871 · Cited by 3 · see citing works

Synthetic Immunology—Building Immunity from the Bottom‐Up with Synthetic Cells

Staufer, O. (2024) · Advanced NanoBiomed Research · doi:10.1002/anbr.202400037 · Cited by 8 · see citing works

A synthetic biology approach to engineering circuits in immune cells

Hoces, D., Blanco, J. M., & Hernández-López, R. A. (2023) · Immunological Reviews · doi:10.1111/imr.13244 · Cited by 18 · see citing works